secwatch.observer — SEC 8-K summary
======================================

Issuer:     Better Therapeutics, Inc. (—)
CIK:        0001832415
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0000950170-23-065185
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Better Therapeutics CFO Mark Heinen resigns; CEO Frank Karbe takes over as principal financial officer
--------------------------------------------------------------------------------

- CFO Mark Heinen resigned effective Nov 27, 2023, as part of expense reduction measures.
- CEO Frank Karbe assumes principal financial officer duties; controller Leslie Miller becomes principal accounting officer.
- Miller receives a base salary increase and annual incentive compensation upon appointment.
- Measures include voluntary salary reductions by CEO and other executives to extend cash runway for AspyreRx.
- Resignation not due to any disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/bttx-20231117.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-065185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer